HLB Receives CRL from FDA for Liver Cancer Drug Due to CGMP Deficiencies
HLB's US subsidiary Elevar Therapeutics received a Complete Response Letter from the FDA for its liver cancer drug combination of rivoceranib and camrelizumab as first-line treatment.
The FDA cited CGMP deficiencies at a facility during inspection, noting that the deficiencies may not be specific to HLB's application.
HLB plans to promptly address the issues and resubmit the application. There is no impact on capital structure or shareholder return policies.
[AI Summary]The CRL delays the approval timeline for HLB's liver cancer drug and may negatively impact short-term stock price. However, the issue is related to manufacturing facility compliance rather than drug efficacy, and does not affect HLB's financial structure or capital position.
KOSDAQ Filing Information
Other Management Matters (Voluntary Disclosure) – HLB Liver Cancer First-Line Treatment (Rivoceranib, Camrelizumab Combination Therapy) Receives Complete Response Letter (CRL) from FDA